INDUCTION OF POLYMORPHIC 4'-HYDROXYLATION OF S-MEPHENYTOIN BY RIFAMPICIN

被引:93
作者
ZHOU, HH
ANTHONY, LB
WOOD, AJJ
WILKINSON, GR
机构
[1] VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232
[2] VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232
关键词
D O I
10.1111/j.1365-2125.1990.tb03799.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Studies were performed in 13 healthy subjects to determine whether treatment with rifampicin results in induction of the metabolism of mephenytoin. Daily dosing with 600 mg rifampicin for 22 days caused a three to eightfold increase in the 0‐8 h urinary R/S ratio of mephenytoin following oral administration (100 mg) of racemic drug to extensive metabolizers of the anticonvulsant. This was accompanied by a 40 to 180% increase in the 0‐8 h urinary excretion of the 4′‐hydroxy metabolite. Four weeks after discontinuing rifampicin, both metabolic indices had returned to their baseline values. By contrast, rifampicin had no effect on either measures of metabolism in subjects of the poor metabolizer phenotype. Thus, it appears that the activity of the enzyme (P‐450 MP) mediating the genetically determined 4'‐hydroxylation of S‐ mephenytoin can be significantly modulated by enzyme inducing agents such as rifampicin and possibly environmental agents with a similar ability. 1990 The British Pharmacological Society
引用
收藏
页码:471 / 475
页数:5
相关论文
共 23 条
[1]   EFFECTS OF KETOCONAZOLE ON THE POLYMORPHIC 4-HYDROXYLATIONS OF S-MEPHENYTOIN AND DEBRISOQUINE [J].
ATIBA, JO ;
BLASCHKE, TF ;
WILKINSON, GR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (02) :161-165
[2]   RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (08) :1667-1671
[3]   ENZYME-INDUCTION AND BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS [J].
BRANCH, RA ;
HERMAN, RJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 :S77-S84
[4]   AGE-ASSOCIATED STEREOSELECTIVE ALTERATIONS IN HEXOBARBITAL METABOLISM [J].
CHANDLER, MHH ;
SCOTT, SR ;
BLOUIN, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (04) :436-441
[5]   THE INFLUENCE OF ENZYME-INDUCTION ON POLYMORPHIC SPARTEINE OXIDATION [J].
EICHELBAUM, M ;
MINESHITA, S ;
OHNHAUS, EE ;
ZEKORN, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) :49-53
[6]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[7]  
FUNCKBRENTANO C, 1989, J PHARMACOL EXP THER, V249, P134
[8]   GENETICALLY-DETERMINED INTERACTION BETWEEN PROPAFENONE AND LOW-DOSE QUINIDINE - ROLE OF ACTIVE METABOLITES IN MODULATING NET DRUG EFFECT [J].
FUNCKBRENTANO, C ;
KROEMER, HK ;
PAVLOU, H ;
WOOSLEY, RL ;
RODEN, DM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (04) :435-444
[9]  
GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243
[10]   KINETICS OF HEXOBARBITAL AND DIPYRONE IN CRITICAL CARE PATIENTS RECEIVING HIGH-DOSE PENTOBARBITAL [J].
HEINEMEYER, G ;
GRAMM, HJ ;
SIMGEN, W ;
DENNHARDT, R ;
ROOTS, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (03) :273-277